Curated news and analysis on clinical trials, drug approvals, and medical research.
New antibody-based approaches demonstrate clinical benefits across multiple cancer types, including improved survival in triple-negative breast cancer, enhanced tumor detection via PET imaging, and activity in relapsed mantle cell lymphoma.
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.
Colorectal cancer rates are rising 3% annually in adults under 50, prompting expanded screening efforts and new treatment approaches. Recent research shows promise in combination immunotherapy and vaccine strategies for advanced disease.
Multiple people were arrested following a city-wide narcotics enforcement operation in Hartford, Connecticut. Police seized over 1,000 sleeves of fentanyl, crack cocaine, a firearm, and more than $8,000 in cash.
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
A longitudinal study of 460,000 teenagers found that adolescent cannabis use increases the risk of developing bipolar and psychotic disorders by twofold, as well as raising risks for depression and anxiety.
Research communities in the US and UK face funding disruptions as governments demand greater alignment with national priorities. UKRI has paused grant programs while early-career researchers advocate for increased NIH funding.
Researchers have developed advanced platforms to study human neural networks, including 3D bioelectronics for brain organoids and scalable 2D neuron networks that reveal brain-like rhythms and drug responses.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
Measles cases are reappearing across the United States, challenging health systems unprepared for a disease declared eliminated in 2000. Clinical leaders must ensure rapid identification, isolation protocols, and vaccination strategies to prevent outbreaks.
Proteolysis-targeting chimeras (PROTACs) are advancing from experimental to clinical-stage cancer therapies, with first candidates entering Phase III trials. The technology degrades target proteins rather than blocking them, offering new options for previously undruggable targets.
Agentic AI models are streamlining oncology clinical trial design and reducing phase II to III failure risk. Separately, Aethlon Medical progresses its Hemopurifier device trial in Australia with strong safety data and accelerated patient recruitment.
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
CellProthera plans to launch a Phase III trial of its ProtheraCytes stem cell therapy for heart failure patients in Q1 2027, enrolling 300-400 patients across 50 sites. The company acquired a transendocardial catheter from Celyad Oncology for €5 million to enable precise delivery of the therapy.
Diacerein, an anthraquinone derivative, shows promise as a disease-modifying agent in rheumatoid arthritis through its anti-inflammatory and chondroprotective actions, with combination therapy appearing to enhance therapeutic benefits.
Mayo Clinic is pursuing two distinct nanoparticle-based cancer treatments: milk-derived nanoparticles for targeted gene therapy in bile duct cancer, and magnetic nanoparticle hyperthermia for metastatic solid tumors.
The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.
The American Psychiatric Association will include biomarkers in the next DSM edition, though such markers remain unvalidated for routine clinical use. Research has spanned decades with limited adoption despite potential to guide treatment selection.
